Amgen

Open: 237.91 Close: 243.28 Change: 5.37

The best way to get informed about Amgen Stock without reading hundreds of pages.

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, price, …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

62 analysts offering price forecasts for Amgen have a median target of 249.55, with a high estimate of 310.00 and a low estimate of 182.00. The projected annual revenue for AmGENis 27,680MM, an increase of 4.13%.

Today's News

Amgen stock has received a consensus rating of hold. 62 analysts offering price forecasts for Amgen have a median target of 249.55, with a high estimate of 310.00 and a low estimate of 182.00. Analyst Price Forecast Suggests 10.53% Upside as of August 2, 2023, the average one-year price target for Amgen is 255.00. The projected annual revenue for AmGENis 27,680MM, an increase of 4.13%. The average annual non-GAAP EPS is 18.93. Amgen announces webcast of 2023 second quarter financial results. The company will report its second quarter results on August 3, 2023. Amgen highlights positive phase ii lumakras data in colorectal cancer amid flat q2 sales. Amgen announced achievement of First-Patient-In for the Amgen-sponsored Phase 1/2 clinical trial evaluating the combination of IDE397 and AMG 193 in patients having tumors with MTAP deletion. The company also raised its outlook for Tags Biotechnology pharmaceuticals. Amgen expects full-year earnings in the range of $17.80 to $18.80 per share. Amgen shares have dropped 12% since the beginning of the year, while the S&Ps 500 index has climbed 17%. Amgen beat on estimates with its Q2 earnings. In 2022, Amgens revenue was $26.32 billion, an increase of 1.32% compared to the previous years $25.98 billion. Shares of Amgen AMGN and Microsoft MSFT have contributed around a quarter of the indexs intraday rally, as the Dow DJIA is trading 176 points higher. Amgen Inc. Yield 2.91% (Analysts price target is $254.12) biotechnology / pharmaceutical The Panic-Proof Portfolio (Stockchase Research) $236.640 Unknown Unlock Rating. Amgen reported revenue of $6.99 billion, up 6% from a year earlier. Product sales by volume grew 11%, but net selling prices fell 2%. Amgen shares were up about half a percentage point at $232 after hours. Amgen Inc. (NASDAQ:AMGN) Dividend Will Be Increased To $2.13 per share dividend for the third quarter of 2023. Amgen is one of the largest biotechnology companies in the world.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, price, quarter, share, target, estimate, revenue, and the most common words in the summary are: amgen, stock, market, inc, price, news, job, . One of the sentences in the summary was: 62 analysts offering price forecasts for Amgen have a median target of 249.55, with a high estimate of 310.00 and a low estimate of 182.00. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #market #inc #price #news #job.